Patent application number | Description | Published |
20080318253 | PSCA prostate stem cell antigen and uses thereof - The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors. | 12-25-2008 |
20080318254 | PSCA antibodies and hybridomas producing them - The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors. | 12-25-2008 |
20090104631 | PSCA: PROSTATE STEM CELL ANTIGEN AND USES THEREOF - The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors. | 04-23-2009 |
20090130108 | N-Cadherin and Ly6 E: Targets for Cancer Diagnosis and Therapy - The present invention provides methods of diagnosis, providing a prognosis and a therapeutic target for the treatment of cancers that overexpress N-cadherin and Ly6-E, including prostrate and bladder cancers. The invention further provides methods of drug discovery to identify pharmaceutical agents that inhibit or prevent the binding of N-cadherin and Ly6-E to its receptor, which are useful when used alone or in combination with known chemotherapeutics, immunotherapeutics, and radiotherapy for the reversal of resistance, tumor progression, and metastasis of cancers associated with the overexpession of N-cadherin and Ly6-E. | 05-21-2009 |
20090311181 | Engineered Anti-Prostate Stem Cell Antigen (PSCA) Antibodies for Cancer Targeting - The invention provides novel humanized antibody fragments that specifically bind prostate cell-surface antigen (PSCA), a protein which is overexpressed in variety of cancers, including prostate, bladder, and pancreatic cancer. Methods are provided for the use of the compositions of the invention for the treatment of cancer, diagnosis of cancer, to provide a prognosis of cancer progression, and for cancer imaging. | 12-17-2009 |
20100119527 | N-CADHERIN: TARGET FOR CANCER DIAGNOSIS AND THERAPY - The present invention provides methods of diagnosis, providing a prognosis and a therapeutic target for the treatment of cancers that express N-cadherin, including prostrate and bladder cancers. | 05-13-2010 |
20100233170 | Fully human antibodies against N-Cadherin - The present application provides fully human antibodies against N-Cadherin for therapeutic and diagnostic methods in cancer. | 09-16-2010 |
20100278821 | N-CADHERIN: TARGET FOR CANCER DIAGNOSIS AND THERAPY - The present invention provides methods of diagnosis, providing a prognosis and a therapeutic target for the treatment of cancers according to their expression of N-cadherin, including prostrate and bladder cancers. | 11-04-2010 |
20100297004 | HIGH AFFINITY ANTI-PROSTATE STEM CELL ANTIGEN (PSCA) ANTIBODIES FOR CANCER TARGETING AND DETECTION - The present invention provides novel high affinity antibodies and fragments thereof that bind to the cancer antigen PSCA. The antibodies of the present invention may be used for cancer diagnosis, prognosis, treatment, visualization, and the like. The present invention also provides methods for the detection, visualization, and treatment of various cancers expressing PSCA. | 11-25-2010 |
20110086029 | NOVEL ANTIBODIES AGAINST CANCER TARGET BLOCK TUMOR GROWTH, ANGIOGENESIS AND METASTASIS - The present invention provides antibodies that target the first-third domains of N-cadherein and the fourth domain of N-cadherin, for diagnosis and therapy of cancers related to N-cadherein. Methods of diagnosis and treatment utilizing these antibodies are also described. | 04-14-2011 |
20110142838 | NOVEL ANTIBODIES AGAINST CANCER TARGET BLOCK TUMOR GROWTH, ANGIOGENESIS AND METASTATIS - The present invention provides antibodies that target the first-third domains of N-cadherein and the fourth domain of N-cadherin, for diagnosis and therapy of cancers related to N-cadherein. Methods of diagnosis and treatment utilizing these antibodies are also described. | 06-16-2011 |
20120063999 | PSCA: PROSTATE STEM CELL ANTIGEN AND USES THEREOF - The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors. | 03-15-2012 |
20120077962 | HUMANIZED ANTI-PROSTATE STEM CELL ANTIGEN MONOCLONAL ANTIBODY - Prostate stem cell antigen (PSCA) is expressed in the majority of prostate cancer patients, making it an ideal target for cancer immunotherapy. Murine monoclonal antibody 1G8 binds to PSCA with nanomolar affinity, but its efficacy as a therapeutic agent is limited by the generation of a HAMA response. The present invention discloses humanized 1G8 antibodies in which the majority of the mouse-derived epitopes have been removed. These humanized antibodies bind PSCA with high affinity and specificity, and have been shown to reduce human bladder tumor take in a nude mouse model. These characteristics make the humanized antibodies of the present invention attractive agents for the treatment and detection of tumors expressing PSCA. | 03-29-2012 |
20130137584 | NOVEL DIAGNOSTIC AND THERAPEUTIC TARGETS ASSOCIATED WITH OR REGULATED BY N-CADHERIN EXPRESSION AND/OR EPITHELIAL TO MESENCHYMAL TRANSITION (EMT) IN PROSTATE CANCER AND OTHER MALIGNANCIES - The present invention provides methods of diagnosing a cancer or providing a prognosis for a cancer by analyzing the level of expression of a marker that is a downstream target of N-cadherin. | 05-30-2013 |
20130274128 | GENE EXPRESSION IN N-CADHERIN OVEREXPRESSING PROSTATE CANCERS AND THEIR CONTROLS - The present invention provides methods of diagnosing a cancer or providing a prognosis for a cancer by analyzing the level of expression of a marker that is a downstream target of N-cadherin. | 10-17-2013 |
20140017240 | Fully Human Antibodies Against N-Cadherin - The present application provides fully human antibodies against N-Cadherin for therapeutic and diagnostic methods in cancer. | 01-16-2014 |
20140220005 | N-Cadherin: Target for Cancer Diagnosis and Therapy - The present invention provides methods of diagnosis, providing a prognosis and a therapeutic target for the treatment of cancers that express N-cadherin, including prostrate and bladder cancers. | 08-07-2014 |
20140364591 | PSCA: PROSTATE STEM CELL ANTIGEN AND USES THEREOF - The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors. | 12-11-2014 |